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Abstract
Acute myocardial infarction and coronary artery disease (CAD) are the most common 
causes for the development of malignant arrhythmia often leading to cardiogenic shock 
and cardiac arrest. Structural heart disease represents the main pathology in older 
patients, whereas young adults mostly suffer from cardiomyopathies and channelopa-
thies. This book chapter delineates modern interventional therapies for patients with 
cardiogenic shock or aborted cardiac arrest. Epidemiological data on the incidence of 
malignant arrhythmia depending causing cardiac arrest depending on the presence or 
absence of CAD and myocardial infarction are presented. Realistic difficulties within 
clinical decision-making are counterbalanced for and against an early, aggressive and 
invasive therapeutic approach including early coronary angiography with percutaneous 
coronary intervention (PCI), targeted temperature management and mechanical cardiac 
assist devices, depending on the individual clinical presentation and underlying cardiac 
arrhythmia.
Keywords: cardiac arrest, assist device, shock, ventricular fibrillation, ventricular 
tachycardia, coronary artery disease
1. Introduction
In recent decades, cardiovascular mortality has been reduced by effective prevention of risk fac-
tors and development of coronary heart disease (CAD) or progressive heart failure syndrome 
[1]. Nevertheless, cardiovascular disease accounts for 17 million deaths per year, of which 25% 
are related to cardiac arrest with consecutive sudden cardiac death (SCD) [1]. The risk of SCD 
was shown to be higher in men and increasing age, alongside with an increasing age-dependent 
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prevalence of CAD. European guidelines estimate SCD occurring in about 1.40/100,000 person-
years in women, and even higher in about 6.68/100,000 person-years in men. Accordingly, the 
estimated annual death rate ranges in between 1100 and 9000 in Europe [1].
There are multiple varying causes for development of cardiac arrest. Structural heart diseases 
are present at older age, including CAD, heart valve diseases and heart failure syndrome, 
whereas in younger adults, cardiac arrest is more often caused by cardiomyopathies, chan-
nelopathies, myocarditis and substance abuse [1].
This chapter summarizes current knowledge of patients with cardiac arrest and concomitant 
CAD. Current knowledge about epidemiological data on the incidence of malignant arrhyth-
mias causing cardiac arrest depending on the presence or absence of CAD is presented. 
Furthermore, the potential benefits of an early coronary revascularization as well as of a prompt 
complete coronary revascularization compared to treatment of coronary culprit lesion only are 
outlined. Finally, the advantages of invasive therapies for patients surviving cardiac arrest, such 
as targeted temperature management and mechanical cardiac assist devices, are elucidated.
2. Prevalence of CAD in patients with malignant cardiac arrhythmia
This chapter subsumes asystole, ventricular tachycardia, ventricular storming and ventricular 
fibrillation under the term malignant arrhythmia.
Prior structural heart disease may be present in almost 50% of patients suffering from cardiac 
arrest, whereas an even higher rate of subclinical CAD is suspected in these patients. Over 
decades, medical research has focused on the detection of reliable risk markers for the devel-
opment of malignant arrhythmia in order to reliably estimate the chance for their individual 
occurrence. The most robust indicator represents the degree of left ventricular (LV) dys-
function according to LV ejection fraction (LVEF). In addition, screening includes all known 
cardiovascular risk factors, such as increases of low-density lipoprotein (LDL) cholesterol, 
smoking status, presence of diabetes mellitus, arterial hypertension and obesity. The imple-
mentation of screening methods to assess patients´ individual cardiovascular risk, as well as 
effective diagnostics and treatment of CAD and heart failure has helped to prevent approxi-
mately 40% of SCD cases [2].
The overall rate of primary ventricular fibrillation or pulseless ventricular tachycardia (pVT) 
as the initial documented heart rhythm in clinical arrest settings varies between 25 and 79% 
in US registries in 2007, especially when occurring in public daily life [3]. In contrast, an 
increase of pulseless electrical activity (PEA) and asystole was documented alongside with 
a decrease of ventricular fibrillation and pVT. This inversion may be explained by improved 
medical care including improved guideline-based drug treatment for CAD and heart failure, 
percutaneous coronary intervention (PCI), implantable cardioverter-defibrillators (ICD), and 
the associated increasing prevalence of end-stage heart failure syndrome, which is associated 
with a higher prevalence of combined PEA or asystole at final disease stages [4, 5]. Survival 
rates are higher after cardiac arrest when a shockable ventricular arrhythmia (pVT or ven-
tricular fibrillation) is documented (30.5%), whereas survival is lower in the presence of PEA 
or asystole (only 7.5–8%) [6].
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Clinically relevant CAD with critical coronary arterial stenoses requiring PCI was shown in 
approximately 75% of patients with cardiac arrest [7, 8]. In the presence of an acute coronary 
syndrome, about 6% of these patients sustain pVT or ventricular fibrillation within the first 24 h 
after symptom onset [1]. There is currently no detailed information available on the exact prev-
alence of CAD depending on the different types of malignant arrhythmia. This is partly due 
to lack of representative prospective studies or registries including either preselected cohorts 
with smaller patient numbers and short follow-up periods. Currently running registries are:
• Parisian Region Out of Hospital Cardiac Arrest (PROCAT; [9]),
• Minnesota Resuscitation Consortium (MRC; [10]),
• Resuscitation Outcomes Consortium (ROC; [11]),
• Emergency Cardiopulmonary Bypass (ECPB; [12, 13]),
• Registry of Malignant Arrhythmias and Sudden Cardiac Death – Influence of Diagnostics 
and Interventions (RACE-IT; clinicaltrials.gov identifier: NCT02982473),
• Extracorporeal Life Support Organization (ELSO; https://www.elso.org).
Furthermore, empirical data about the influence of CAD specific therapies on the different 
malignant arrhythmia are inconclusive. This implies in particular the influence of coronary 
revascularization by PCI or aortocoronary bypass surgery (CABG), targeted catheter-based 
ablation of ventricular tachycardia or supply by ICD on long-term course of patients with 
aborted cardiac arrest. Accordingly, mortality data depending on the underlying cardiac 
arrhythmia in patients being treated by modern cardiological therapies are not well repre-
sented in recent studies [1]. Table 1 summarizes the most important empirical data on CAD, 
malignant arrhythmia and cardiac arrest.
• The risk of SCD is higher for men and increases with age.
• Incidence of SCD: approx. 1.40/100,000 person-years in women, whereas 6.68/100,000 person-years in men.
• The annual death rate of SCD ranges from 1100 to 9000 in Europe.
• Causes:
 ○ Young adults: cardiac channelopathies, cardiomyopathies, myocarditis and substance abuse.
 ○ Older adults: degenerative heart disease such as CAD, valvular heart disease and heart failure.
• Structural heart disease is already known in about 50% of patients.
• Active screening for cardiovascular risk factors and early detection and treatment of CAD and heart failure 
prevents 40% of SCD cases.
• A shockable initial rhythm (VF, pVT) is associated with a higher survival rate compared to asystole and PEA.
• The rates of asystole and PEA as initial arrhythmia in cardiac arrest are increasing.
• CAD requiring intervention is present in up to 75% of patients with survived cardiac arrest.
• Patients with persistent coma after cardiac arrest are associated with a higher mortality of up to 50%.
Table 1. Empirical data on coronary artery disease (CAD), malignant cardiac arrhythmia and cardiac arrest.
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3. Value of early invasive coronary diagnostics and therapies after 
cardiac arrest
The biological processes that cause an arrested heart either to regain a regulated sinus rhythm 
with sufficient myocardial contraction and stroke volume or not to recover adequately after 
an acute myocardial infarction are still unclear [4]. The reperfusion-damage theory is often 
debated, which has to be prevented by coronary revascularization and reperfusion. Still vital 
myocardium is threatened not only by cell death under circumstances of ongoing ischemia, 
but also by changes in cell metabolism and the sudden resupply of oxygen and other sub-
strates after reperfusion [14]. Whether re-exposure to normal concentrations of oxygen, cal-
cium or a balanced pH value may have beneficial or even fatal effects following successful 
reperfusion of a closed coronary artery is poorly understood and very controversial [15, 16]. 
It is assumed that the reperfusion damage is subject to temporal dynamics. After a prolonged 
ischemic phase, there is a critical time frame in which reperfusion may cause even more harm 
than benefit [17]. This has been proven in studies investigating ischemic preconditioning. 
Here, repetitive periods of iatrogenic induced complete ischemia may reveal myocardial pro-
tection and may reduce the reperfusion damage [18].
Today, emergency PCI combined with an extracorporeal bypass is one of the favored revas-
cularization strategies. Emergency bypass requires rapid cannulation of a large central artery 
and vein, typically femoral artery and vein, and can be inserted out-of-hospital already [12, 
19]. Since 2000, those concepts have been pushed forward. For instance, more than 30 car-
diac arrest centers were created in Japan to establish full cardiovascular support and emer-
gency PCI support within 15 min, achieving a survival rate of more than 15% in cardiac arrest 
patients with good neurological function [7]. The administration of additional intravenous 
drug combinations as a so-called “anti-perfusion-damage cocktail” is another concept that 
has so far only been evaluated in experimental work [4, 20].
In case of an established emergency bypass protected emergency PCI can be performed safer. 
Emergency PCI represents the decisive therapy in cardiac arrest patients, which may prevent 
ongoing myocardial necrosis. In addition, the baseline neurological status of each individual 
patient is directly related to mortality after cardiac arrest. About two-thirds of all patients with 
out-of-hospital cardiac arrest caused by ST segment elevation myocardial infarction (STEMI) 
are in a comatose state. In particular, this group of patients is associated with a significantly 
higher mortality of 50%, compared with a mortality of only 5% in awake patients after being 
successfully resuscitated [21].
About 50% of patients surviving out-of-hospital cardiac arrest and with proven CAD reveal 
acute coronary artery occlusion [7]. Therefore, European guidelines recommend primary PCI 
in patients with a successfully restored spontaneous circulation (ROSC) after cardiac arrest, 
cardiopulmonary resuscitation (CPR) in the presence of STEMI, regardless of baseline neu-
rological status (recommendation class I, level of evidence B) [1, 7, 9]. In contrast, coronary 
angiography should also be performed independently of ECG findings in survivors of car-
diac arrest with an intermediate pretest probability, which is estimated on the basis of age, 
gender and symptoms (recommendation grade IIa, level of evidence B-C [1, 22, 23]. This 
also includes patients with “ventricular storming” (recommendation grade IIa, level of evi-
dence C [22]). According to various mostly nonrandomized studies, early invasive coronary 
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 angiography may lead to increasing one-year survival in up to 60%. Still 58% of patients 
 without ST-segment elevation reveal a critical coronary arterial stenosis (“culprit lesion”) [6, 9, 
24, 25]. Again, most studies investigating patients suffering from acute coronary syndrome 
and malignant arrhythmia were observational and heterogeneous including both patients 
with STEMI and NSTEMI [26]. Invasive coronary angiography with PCI should be performed 
either immediately or as early as possible based on careful clinical assessment [6]. This con-
cept is also supported by animal studies demonstrating an improvement of both survival and 
neurological function after immediate reperfusion therapy in pigs with induced ischemia-
driven ventricular fibrillation [27]. A fortiori, further clinical parameters become considerably 
important, which in turn may limit the use of an early PCI in the individual (Table 2).
These parameters include the following: [6]
• unwitnessed cardiac arrest;
• absence of ventricular fibrillation as primary arrhythmia;
• absence of bystander CPR;
• prolonged or repeated CPR;
• CPR period longer than 30 min;
• lactate value >7 mmol/L, pH value <7.2 both being associated with severe tissue hypoxia 
and multiple organ failure;
• age > 85 years;
• terminal renal failure requiring renal replacement therapy; and
• presence of noncardiac causes leading to cardiac arrest.
• Unwitnessed cardiac arrest
• Absence of ventricular fibrillation as primary arrhythmia
• Absence of bystander CPR
• Prolonged or repeated CPR
• CPR period longer than 30 min
• Lactate value >7 mmol/L, pH value <7.2 both being associated with severe tissue hypoxia and multiple organ 
failure
• Age > 85 years
• terminal renal failure requiring renal replacement therapy
• Presence of noncardiac causes leading to cardiac arrest
• Patients with noncardiac causes of cardiac arrest
• Advanced dementia
• Persistent ventilation
• Frailty
• Multisystem disorders
Table 2. Important clinical parameters limiting prognosis and the additional benefit of an early aggressive invasive 
treatment strategy by PCI.
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Other factors to consider include comorbidities such as advanced dementia, persistent 
mechanical ventilation, respiratory failure, frailty, physical or neurological disability and 
multisystemic disorders. All these factors should be taken into account independently of the 
documented primary arrhythmia on ECG because they postpone the indication for early inva-
sive diagnostics and therapies.
Figures 1 and 2 show two emergency complex multiple PCIs in two patients in cardiogenic 
shock after impending or survived cardiac arrest using two different cardiac/ventricular assist 
devices (VAD) as extracorporeal life support (ECLS).
Figure 1. Emergency coronary angiography of a 82-year-old female patient surviving out-of-hospital cardiac arrest 
with immediate nonprofessional resuscitation. Ventricular fibrillation was documented as primary arrhythmia, with 
consecutive 15-min of CPR, multiple external electrical defibrillations and final ROSC. Severe coronary 3-vessel 
disease was found, with a chronic total occlusion of the right coronary artery (CTO) with ipsilateral and contralateral 
retrograde collateral connections (A). The left coronary artery shows a critical 99% stenosis at the distal main trunk 
(LMT), progressing into the central left circumflex (CX) (B) and left artery descending (LAD). LAD additionally 
shows sequential high-grade 99% proximal and mid-stenoses (C). By implantation of a venous-arterial extra-corporal 
membrane oxygenation (VA-ECMO) via the left femoral artery and vein hemodynamic collapse was rapidly stabilized 
and complex multivessel PCI could have been initiated (D). First, rotablation (1.25 mm burr) from the LMT into the 
middle LAD (E). Secondly, single PCI/DES implantation was performed at mid-LAD (Boston Syndrome II 2.5/16 mm). 
Finally, bifurcational PCI of LMT-CX-RIVA T-stenting with antegrade protrusion (TAP) technique and final balloon 
kissing was performed (LMT in CX, Boston Synergy 4.0 / 24 mm; LMT in LAD protruded, Boston Synergy II 3.0/16 mm; 
final kissing with non-compliant balloons, Boston Emerge 4.0/20 and 3.5/15 mm) (F). Weaning from VA-ECMO and 
mechanical ventilation succeeds on the following day and the patient could have been discharged from hospital at day 
9 in stable neurological and cardiopulmonary status.
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4. Emergency PCI with complete coronary revascularization or 
treatment of the coronary “culprit lesion” only?
European guidelines recommend immediate coronary revascularization in patients with 
recurrent ventricular tachycardia or fibrillation, in order to prevent suspected myocardial 
ischemia. However, graduation of recommendation is based on expert consensus only (grade 
of recommendation I, level of evidence C; [1, 22]). On the other hand, the SYNTAX trial dem-
onstrated that complete compared to incomplete coronary revascularization (either by PCI 
or CABG) significantly improves long-term survival of patients with coronary three-vessel 
Figure 2. Severe coronary artery disease of a 50-year-old male patient with ST segment elevation myocardial 
infarction (STEMI) of the anterior wall, consecutive cardiogenic shock and prolonged cardiac arrest. Coronary 
angiography showed a subtotal stenosis of the mid and distal LMT, LAD showed long and critical stenosis, CX 
and first marginal branch were also highly stenosed (A&B). Right coronary artery was normal (not shown). Firstly, 
percutaneous and central intracardiac LVAD (Impella 2.5) was inserted into the left ventricle (C). Secondly, the LMT-
LAD-CX bifurcation was predilated by a kissing balloon technique (D). Thirdly, rotablation (1.25 mm burr) of the 
mid CX was performed (E). Finally, complex multivessel PCI of marginal branch, CX and LAD. Final result showed 
sufficient TIMI-III flow with complete emergency revascularization (F). Impell device was removed after PCI due to 
recovery of circulation.
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disease [28]. In cardiogenic shock, early coronary revascularization was associated with 
improved long-term survival compared to drug therapy [29, 30]. However, early PCI in 
cardiogenic shock or in patients with aborted cardiac arrest is applied in 50–70% of patients 
only [31], although most of these patients reveal coronary multivessel disease being associ-
ated with significantly higher mortality compared to coronary one-vessel disease [32, 33]. 
Depending on hemodynamic instability and complexity of multivessel coronary disease 
according to the SYNTAX level, either a PCI or CABG may be the recommended treat-
ment option in cardiogenic shock (Grade I, Level B evidence) [22]. The “CULPRIT-SHOCK” 
study recently demonstrated a prognostic benefit for a staged PCI of the “culprit lesion” 
at first in patients with cardiogenic shock and coronary multivessel disease compared to 
“ad-hoc” multivessel PCI directly at presentation. This prognostic benefit was attributed 
to fewer amount of contrast use and consecutive fewer rates of renal failure, when the cul-
prit lesion was treated at first presentation and all other critical coronary artery stenoses 
underwent PCI some days later after hemodynamic recovery [34, 35]. Comparative studies 
evaluating CABG versus PCI in patients suffering from cardiac arrest or cardiogenic shock 
are lacking [36]. However, the advantages for immediate PCI consist of a better accessibility 
of cardiac catheterization laboratories compared to cardiac surgery units, including rapid 
feasibility of PCI with minimally invasive access. This has led to an almost lower prevalence 
of emergency CABG in post-cardiac arrest patients of less than 5% [31].
5. Additional benefit of interventional and surgical treatment 
options after cardiac arrest
Beside revascularization therapy of all critical coronary artery stenoses or occlusion, further 
interventional and surgical therapeutic option have become available for patients after car-
diac arrest. These advanced therapies reveal two main therapeutic goals:
1. cerebral neuroprotection and myocyte protection after episodes of ongoing hypoxemia 
during cardiac arrest; and
2. restoration of hemodynamic stability in cardiogenic shock.
5.1. Targeted temperature management
Cerebral and myocardial protection can be achieved by myocardial reperfusion and tar-
geted temperature management (TTM). The TTM may attenuate various signaling path-
ways leading to cell death by revealing anti-apoptotic and anti-inflammatory effects [37]. 
Smaller cohort studies demonstrated that invasive treatment after cardiac arrest including 
TTM and coronary angiography with reperfusion therapy by PCI can reduce myocardial 
infarction size [38]. In addition, it could have been shown that TTM alone without reperfu-
sion reveals adverse effects because the extent of myocardial infarction was comparable 
independently of treatment with TTM. TTM plus reperfusion resulted in the best  recovery 
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of cardiac function with the lowest myocardial infarction size [39]. This experimental evi-
dence confirms the disadvantage of delayed coronary revascularization and limits the ben-
efit of sole TTM after cardiac arrest.
In contrast, Mooney et al. demonstrated that delayed initiation of TTM in patients with out-
of-hospital cardiac arrest was associated with a 20% increase of mortality. However, the rate 
of invasive coronary angiography was 72% with a PCI rate of 40% only [40]. It is well docu-
mented from several cohort studies that a combined PCI plus TTM improves survival and 
neurological outcome in patients with cardiac arrest and persistent coma [6].
TTM consists of controlled intravenous infusion systems (e.g., Bogard XP® Temperature 
Management System, ZOLL Medical Corporation, Asahi Kasei Corp, Japan) in combination 
with cool packs. TTM may not be initiated out-of-hospital only in order to achieve potentially 
best possible prognostic and neurological outcome [41, 42]. The target temperature is aimed 
between 32 and 36°C, whereas even lower target temperatures were shown to have no addi-
tional prognostic or neurological benefit [37, 43, 44]. Regardless of the documented primary 
arrhythmia, TTM is always recommended for at least 24 h duration in patients with persistent 
coma [37].
5.2. Cardiac assist devices for extracorporeal life support (ECLS)
Despite successful CPR and consecutive ROSC, there are still 30–40% of patients revealing 
hemodynamic instability and prolonged cardiogenic shock. In this situation, cardiac ventricu-
lar assist devices (VAD) may achieve stabilization or normalization of circulation. Cardiac 
index may be normalized, myocardial oxygen consumption and perfusion of secondary 
organs including brain and kidneys will be improved [25]. The presence of the acute emer-
gency, in which post-cardiac arrest patients with prolonged cardiogenic shock are situated, 
favors minimally invasive or percutaneous VAD. Depending on the device type, each indi-
vidual VAD increases cardiac output either with left (LV) or right ventricular (RV) mechanical 
support.
Currently available VAD systems for percutaneous access include the following:
• Intra-aortic balloon pump (IABP);
• LVAD – central:
 ○ LV to aorta: non-pulsatile axial Impella® 2.5/5.0 (Abiomed Europe, Aachen, Germany; 
Abb. 3a),
 ○ Left atrium (LA) to aorta: TandemHeart® LVAD KIT (CardiacAssist, Inc., Pittsburgh, 
USA; Abb. 3b);
• RVAD – central:
 ○ Vena cava inferior (VCI) to pulmonary artery (PA): non-pulsatile axial Impella RP® 
(Abiomed Europe, Aachen, Germany; 3a),
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 ○ RA to PA: TandemHeart® RVAD KIT with 2 cannulas (CardiacAssist, Inc., Pittsburgh, 
USA; Abb. 3c),
 ○ RA to PA: TandemHeart® RVAD PROTEKDuo® double lumen cannula (CardiacAssist, 
Inc., Pittsburgh, USA; Abb. 3d);
• Extracorporeal membrane oxygenation (VA [veno-arterial]-ECMO) – peripheral:
 ○ V. femoralis to A. femoralis (VA): CARDIOHELP system (MAQUET GETINGE GROUP, 
Rastatt, Germany) or LIFEBRIDGE® 2.0 Systemccar- dio (ZOLL Medical Deutschland 
GmbH; Abb. 3e).
Unfortunately, scientific evidence about clinical benefits of the various VAD in patients with 
cardiogenic shock, aborted cardiac arrest or persistent ventricular tachycardia or fibrillation 
(“ventricular storming”) is still insufficient and not sound [1, 22, 25, 45]. Recommendation for 
mechanical circulatory support in cardiogenic shock caused by myocardial infarction is based 
purely on expert opinion (grade of evidence IIb, level of evidence C; [22]). VAD were shown 
to stabilize patients suffering from hemodynamically unstable ventricular tachycardia. In 
contrast, VAD may also complicate the therapeutic management in emergency situations 
because clinical application of VAD demands more members of stuff. Additionally, mechani-
cal assist devices were also shown to alleviate the incidence of ventricular tachycardia by the 
VAD itself [1].
Combining PCI with IABP was not associated with a significant reduction of infarct size [46]. 
In particular, IABP was not associated with a reduction of 30-day or 1-year mortality in 
patients surviving cardiogenic shock due to myocardial infarction [47, 48]. Therefore, the use 
of IABP is recommended only in case of mechanical complications in order to bridge the 
patient for cardiac surgery [22, 49].
More and more meta-analyses have recently been published, which conclusively ana-
lyzed smaller studies evaluating the benefit of VAD in patients after cardiac arrest or with 
cardiogenic shock. Ouweneel et al. [50] demonstrated that, after cardiac arrest, the use 
of VA-ECMO significantly improves both survival and neurological outcome at 30 days 
compared to patients treated with IABP or Impella® (n = 219). Even after cardiogenic 
shock, patients treated with VA-ECMO showed a higher survival rate at 30 days com-
pared to patients with IABP or Impella® (n = 151) [50]. In contrast, the direct comparison 
between IABP and Impella® showed differences of survival in patients with acute myo-
cardial infarction and cardiogenic shock [51, 52]. However, it could have been shown 
that the earliest possible use of Impella® reveals an independent prognostic factor for 
improved survival after cardiogenic shock [53–55]. Vase et al. described in a small case 
series (n = 8) that the use of the Impella® after cardiac arrest and mean CPR duration 
with “low-flow-time” of about 50 min is associated with a comparable survival rate to 
cardiogenic shock [56, 57].
Data for VAD between LA and aorta, such as TandemHeart®, are not available for 
patients surviving cardiac arrest or cardiogenic shock. Therefore, no evidence-based rec-
ommendation can be given. However, TandemHeart® was shown as a safe and feasible 
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mechanical circulatory support during high-risk PCI [45]. Specifically, for TandemHeart® 
a transseptal puncture is needed during implantation with trans-septal sheath diameters 
ranging from diameters of 15–16 French. However, transseptal puncture is rarely per-
formed on a regular basis and only by a smaller number of interventional cardiologists. 
This makes the application of TandemHeart® limited for a widespread use in clinical 
practice especially in emergency situations of patients with cardiac arrest and cardiogenic 
shock [45]. In addition, dislocation of the LA cannula into pulmonary veins or left atrial 
appendage during relocation maneuvers or during intensive care transports are potential 
complications.
Data on VA-ECMO in cardiac arrest or cardiogenic shock patients are based on many 
smaller cohort studies published in 2006 in cardiac surgery settings. Here, a meta-analy-
sis demonstrated a survival rate of 50% [11]. The abovementioned ELSO registry reports 
about a survival rate of 27% post cardiac arrest [58]. In 2013, Takayama et al. reported on 
50% survival rate for patients with cardiac arrest or cardiogenic shock after implantation of 
VA-ECMO. Half of these patients needed a permanent surgical VAD at follow-up. Also in 
this cohort, prolonged duration of CPR was associated with increased mortality despite the 
use of VA-ECMO [59].
Modern medical technologies have been developed in recent years, which make VAD appli-
cable for percutaneous access in critical and unstable situations. It should be emphasized 
that mechanical support after cardiac arrest and consecutive cardiogenic shock is not lim-
ited to the left heart only. In principle, and always depending on the underlying individual 
clinical condition, RV support can also be performed by another RVAD at the same time. 
The femoral access route is usually preferred for implantation of the LVAD. For RVAD, both 
the femoral and the transjugular access routes are possible. Direct and central unload of the 
congested heart is always recommended, but depends on technical applicability in each 
individual clinical situation. In contrast, insertion of cannulas at peripheral femoral vessels 
will always provide indirect unload for the congested heart because extracorporeal blood 
re-circulated to peripheral vessels. As a result, contrary effects were recently demonstrated 
for peripheral assist devices (Figure 3d, e, left; [45]). The increasing amount of peripherally 
recirculated blood volume automatically raises wall tension in the peripheral arterial sys-
tem. In turn, this leads to considerable increase of afterload, which may be harmful for the 
congested, severely impaired LV after cardiac arrest. Therefore, the implantation of periph-
eral VA-ECMO systems additionally requires the placement of LA transseptal cannulas, 
which leads to “central unload” at the level of left atrium and the left ventricle (Figure 3e, 
middle; [60]). “Central unload” within the LA was more effective compared to RA because 
LV filling can be reduced from the left atrial level, while at the same time systemic perfusion 
is maintained more effectively. In contrast, unloading at the right atrium was associated 
with a significant increase of LV wall tension and LV unloading becomes even less effective 
[60]. Direct unloading within LA or LV (e.g., in the TandemHeart®) therefore represents the 
most effective way for mechanical circulatory support by VAD [49]. Additional unloading 
is usually achieved by an additionally inserted cannula, which is positioned in the LA after 
transseptal puncture, while it can be integrated into the peripheral VA-ECMO circuit via 
Y-connectors (Figure 3e, right).
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Figure 3. Graphical illustration of different ventricular assist devices (VAD) for extracorporeal life support (ECLS): 
Central left ventricular assist device (LVAD): (A) LV (left ventricular) to aorta: non-pulsatile axial Impella® 2.5/5.0 
(Abiomed Europe, Aachen, Germany). (B) LA (left atrial) to aorta: Tandem Heart® VLAD KIT (Cardiac Assist, Inc., 
Pittsburgh, USA). Central right ventricular assist device (RVAD): (A) Vena cava inferior (VCI) to PA: nonpulsatile axial 
Impella RP® (Abiomed Europe, Aachen, Germany). (C) RA (right atrial) to PA (pulmonary artery): Tandem Heart® 
RVAD KIT with 2 cannulas (Cardiac Assist, Inc., Pittsburgh, USA). (D) RA to PA: Tandem Heart® RVAD PROTEKDuo® 
dual lumen cannula (Cardiac-Assist, Inc., Pittsburgh, USA). Peripheral ECLS: (E) extracorporeal membrane oxygenation 
(VA [veno-arterial] - ECMO): peripheral femoral vein to femoral artery (VA) - ECLS: CARDIOHELP System (MAQUET 
GETINGE GROUP, Rastatt, Germany). (F) Placement of LA cannula (trans-septal) in addition to the VA-ECMO: 
improved “unload” of the congested heart, the additional cannula can be integrated into the VA-ECMO circuit via 
Y-connectors. Unfavorable effects on the cardiovascular system due to peripherally placed assist devices can be reduced.
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6. Conclusions for daily clinical practice
• The grade of recommendation for early invasive coronary angiography with immediate 
PCI in post cardiac arrest patients is still based only on non-randomized cohort studies 
or expert opinions, depending on the pretest probability and on the type of myocardial 
infarction (i.e., NSTEMI or STEMI).
• Decision-making for either an interventional-invasive or surgical approach should always 
include important prognostic cofactors.
• A staged PCI including emergency PCI of the coronary “culprit lesion” only in the emer-
gency setting was shown to be safer and associated with improved survival compared to 
“ad-hoc” emergency PCI of all critical coronary stenoses in patients suffering from cardio-
genic shock and coronary multivessel disease.
• The benefit of emergency CABG compared to emergency PCI after cardiac arrest requires 
further evaluation.
• Advanced interventional and operative therapies include targeted temperature manage-
ment in combination with coronary revascularization and extracorporeal mechanical car-
diac support systems, which include intra-aortic counter pulsation (IABP), central LVAD 
and RVAD, as well as peripheral ECMO systems.
• Randomized prospective studies comparing the use of VAD in post cardiac arrest patients 
is lacking. Use of VAD is still limited to specialized centers and a widespread routine ap-
plication is still a long way off.
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